文章：

从淋巴瘤中“咬”出一口：B细胞非霍奇金淋巴瘤中的双特异性抗体

Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma

原文发布日期：28 April 2024

DOI: 10.3390/cancers16091724

类型: Article

开放获取: 是

英文摘要：

B-cell non-Hodgkin’s lymphoma (NHL) refers to a heterogenous group of diseases, all of which have a wide range of treatment strategies and patient outcomes. There have been multiple novel, immune-based therapies approved in NHL in the last decade, including bispecific antibodies (BsAbs) and chimeric antigen receptor therapy (CAR-T). With a host of new therapies, an important next step will be determining how these therapies should be sequenced in contemporary management strategies. This review seeks to offer a framework for the ways in which BsABs can be incorporated into the current management paradigm for NHL, with special attention paid to diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

摘要翻译： 

B细胞非霍奇金淋巴瘤（NHL）是一组异质性疾病，其治疗策略和患者预后存在显著差异。过去十年中，多种新型免疫疗法在NHL治疗领域获批，包括双特异性抗体（BsAbs）和嵌合抗原受体疗法（CAR-T）。随着新疗法的不断涌现，如何将这些疗法合理排序并整合到现代治疗策略中，成为当前亟待解决的关键问题。本综述旨在构建一个将BsAbs纳入现有NHL治疗体系的框架，重点关注弥漫性大B细胞淋巴瘤（DLBCL）、滤泡性淋巴瘤（FL）和套细胞淋巴瘤（MCL）的治疗路径。

原文链接：

Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma